Hims & Hers (HIMS) Q2 Revenue Jumps 73%
Hims & Hers Health (NYSE:HIMS), a direct-to-consumer digital health platform focusing on telehealth, subscription medications, and personalized care, released its second quarter 2025 results on August 4, 2025. The headline news: GAAP revenue grew sharply to $544.8 million, up 73% year over year, but finished 1.2% below the consensus GAAP estimate of $551.7 million. However, earnings per share (diluted, GAAP) was $0.17, The quarter saw strong subscriber growth and profit expansion, but gross margin (GAAP) decreased to 76% from 81% in Q2 2024 and free cash flow (non-GAAP) turned negative, raising questions around operational investments and cash efficiency compared to the previous year.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Hims & Hers Health offers digital healthcare through a subscription platform, enabling customers to access telehealth consultations, receive prescription treatments, and purchase personalized health and wellness products. Most revenue derives from its direct-to-consumer digital platform. Its model combines telehealth visits, e-commerce, and pharmacy fulfillment, making it easier for consumers to obtain treatments for conditions like hair loss, sexual health, weight management, mental health, and dermatology.
Source Fool.com
